Ann Geriatr Med Res Search

CLOSE


Ann Geriatr Med Res > Volume 30(2); 2026 > Article
Sato, Abe, Kimura, Tanaka, Okuda, Shirahata, Yamamoto, Ide, and Nozoe: Co-existence of Possible Sarcopenia and Dysphagia is Associated with Poor Functional Outcomes in Patients with Acute Stroke: A 1-Year Follow-up Study

Abstract

Background

This study aimed to clarify the association between the co-existence of possible sarcopenia (PS) and dysphagia in patients with acute stroke and the functional outcomes 12 months after stroke.

Methods

This multicenter retrospective cohort study was conducted on patients with stroke admitted to two acute care hospitals in Japan between November 2020 and October 2023. PS was defined based on grip strength (males <28 kg, females <18 kg) and calf circumference (males <34 cm, females <33 cm) on admission. Dysphagia was defined as a Functional Oral Intake Scale score of less than 4. The outcome was defined as a composite of either poor functional outcome (modified Rankin Scale [mRS] score of 3–6) or failure to recover to the premorbid mRS at 12 months after stroke onset. Modified Poisson regression analysis was used to examine the association between the co-existence of PS and dysphagia and poor functional outcomes.

Results

This study included 604 patients (median age 76 years; 367 men). Compared with the non-PS and non-dysphagia group, the PS and dysphagia group had a higher proportion of poor functional outcomes. Subsequently, modified Poisson regression analysis was performed. The interaction between PS and dysphagia was significantly associated with poor functional outcomes (risk ratio=4.348, 95% confidence interval 2.683–7.046).

Conclusion

In patients with acute stroke, the co-existence of PS and dysphagia was associated with poor functional outcomes 12 months after stroke. Future multicenter prospective interventional studies are required to clarify the effectiveness of multifaceted intervention programs in high-risk patients.

INTRODUCTION

Advances in stroke treatment have reduced post-stroke mortality.1) However, stroke remains a leading cause of functional disability worldwide, imposing significant burdens on the affected individuals, caregivers, and healthcare systems.2,3) Furthermore, functional impairments after stroke often lead to reduced quality of life, increased care dependency, and higher institutionalization rates.4-6) Therefore, understanding the factors that negatively affect long-term functional outcomes after stroke is essential for optimal patient recovery and improvement of overall societal health.
Sarcopenia profoundly affects post-stroke recovery.7,8) Characterized by the systemic loss of skeletal muscle mass and strength, sarcopenia is frequently observed in patients with stroke.9) Its prevalence increases from onset through the acute phase to the recovery phase.10) Previous studies have reported an association between sarcopenia and poor outcomes in patients with stroke,7,11) making it an important factor in preventing severe disability in these patients.
Dysphagia also markedly affects the disability trajectory of patients with stroke. It can lead to serious complications such as aspiration pneumonia, malnutrition, and dehydration, which compromise overall health and rehabilitation outcomes.12,13) The profound relationship between sarcopenia and dysphagia is increasingly recognized not only in patients with stroke but also in various older and chronically ill populations.14-17) For example, sarcopenia-related muscle weakness and reduced physical activity can exacerbate swallowing difficulties, while dysphagia-induced malnutrition may conversely accelerate muscle loss.15,18) Individually, both sarcopenia and dysphagia are established risk factors for various adverse outcomes, including increased mortality, prolonged hospital stays, and poorer functional recovery in patients with stroke and other medical conditions.8,19-21) However, in the context of post-stroke recovery, while sarcopenia and dysphagia are individually recognized as risk factors for poor outcomes, the interactive effects of their co-existence and subsequent impact on functional prognosis have not been sufficiently investigated. The possibility that these risk factors not only have additive effects but also interact to exert adverse effects has not yet been investigated. A detailed understanding of how the co-existence of sarcopenia and dysphagia in the acute phase of stroke influences chronic functional outcomes 12 months after onset is indispensable for developing appropriate intervention strategies for high-risk individuals. Therefore, this study aimed to investigate the association between the co-existence of sarcopenia and dysphagia in patients with acute stroke and their functional outcomes 12 months after stroke onset.

MATERIALS AND METHODS

Participants and Setting

This retrospective cohort study was conducted at two acute care hospitals in Niigata and Hyogo, Japan. The inclusion criteria were admission between November 2020 and October 2023 with cerebral infarction or hemorrhage within 48 hours of onset. The presence of stroke was confirmed in all enrolled patients by using computed tomography or magnetic resonance imaging and diagnosis by a medical doctor. The exclusion criteria were missing data, a premorbid modified Rankin Scale (mRS) score of 5, presence of coronavirus disease 2019 (COVID-19) at the time of admission, and refusal to participate in the study. At the hospitals where this study was conducted, a postal survey at 12 months is routinely performed as part of usual clinical care, and the data had already been collected at the time the study was conceived, representing secondary use of routine clinical data.

Rehabilitation during Hospitalization

The rehabilitation program (up to 3 hr/day) was tailored to accommodate individual patients’ functional abilities and disabilities, such as paralyzed limb facilitation, range of motion exercises, basic movement training (mainly for the legs), walking training, resistance training, aerobic exercises using an ergometer aimed at improving endurance, activities of daily living training, and dysphagia rehabilitation.22) These interventions followed the Japan Stroke Society Guidelines for the Treatment of Stroke.23) There was no difference in this rehabilitation concept between the two hospitals included in the study.

Data Collection

Data regarding age, sex, body mass index (BMI), stroke type, lesion side, stroke severity (National Institutes of Health Stroke Scale [NIHSS] score), comorbidities, primary treatment, premorbid and discharge mRS scores, and length of hospital stay were collected from medical records.

Measurement of Possible Sarcopenia

Possible sarcopenia (PS) was defined according to the Asian Working Group for Sarcopenia (AWGS) 2019 criteria, by using calf circumference for case finding (males <34 cm, females <33 cm) and low grip strength for case identification (males <28 kg, females <18 kg).24) Grip strength on the non-paretic side was measured twice by using a Smedley-type hand dynamometer (TKK 5401; Takei Scientific Instruments Co., Ltd., Tokyo, Japan), and the maximum value was recorded. In cases of bilateral paresis, the maximum values from both sides were used. Patients who were unable to undergo grip strength measurements because of impaired consciousness were excluded from the analysis because of missing data. Calf circumference was measured to the nearest 0.1 cm by using a tape measure. This measurement was performed on the non-paretic leg, with the patient in the supine position and the knee flexed to 90° and the ankle relaxed. If no paresis was present, the measurement was performed on both sides, and the maximum value was recorded. Patients with pitting edema were excluded from the analysis because of missing data. All measurements were performed by experienced physical therapists trained in standardized protocols and conducted within 5 days of admission, considering acute-phase treatment.

Assessment of Dysphagia

Swallowing function was assessed using the Functional Oral Intake Scale (FOIS),25) following an initial dysphagia screening performed by speech-language pathologists. The FOIS is a clinical tool used to evaluate a patient’s ability to consume food and liquids. Scores of 1–3 indicate dependence on tube feeding, ranging from no oral intake to minimal oral intake with supplemental tube feeding. Scores of 4–6 reflect partial oral intake with varying dietary restrictions, whereas a score of 7 represents full oral intake without restrictions and is considered to indicate functional normalcy. Based on a previous study,26) dysphagia in this study was defined as a FOIS score of less than 4, indicating a tube feeding-dependent state. A tube feeding–dependent state represents a criterion that objectively identifies severe dysphagia requiring intensive interventions during acute management. Because previous studies26,27) have defined post-stroke dysphagia as a FOIS score of less than 4, the same definition was adopted in this study to ensure comparability with existing evidence. This assessment was conducted within 5 days of admission, considering acute-phase treatment.

Outcomes

The outcome was defined as a composite of either poor functional outcome (mRS score 3–6) or failure to recover to the premorbid mRS at 12 months after stroke onset.28) The mRS score at 12 months was assessed using a mailed self-administered questionnaire or medical record review. The mRS score at admission was assessed by a stroke-trained physician experienced in mRS application according to the following scale, where a score of 0, 1, 2, 3, 4, 5 and 6. Scores of 0 to 6 indicate the following conditions: 0, no symptoms; 1, symptoms are present but there is no significant disability and the patient is able to carry out all usual duties and activities; 2, slight disability, with inability to carry out all previous activities but able to look after own affairs without assistance; 3, moderate disability, requiring some help but able to walk without assistance; 4, moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance; 5, severe disability, bedridden, incontinent, and requiring constant nursing care and attention; and 6, death.29)
Additionally, the number of adverse events was investigated in a supplementary analysis. These included major adverse cardiovascular events (MACEs), defined as rehospitalization or death due to stroke or cardiovascular disease up to 12 months after onset, and non-MACEs. For non-MACEs, information on pneumonia, other medical conditions, falls, and other relevant events was collected. Furthermore, data on all-cause mortality encompassing both MACE and non-MACEs were collected. Outcomes were monitored via mailed, self-administered questionnaires or through a retrospective review of medical records.

Ethics Approval

This retrospective cohort study was approved by the ethics committee of the study center (Approval No. E2024000601) and conducted in accordance with the Declaration of Helsinki. The requirement for informed written consent was waived because of the retrospective design and the use of anonymized data. Instead, the participants were offered the opportunity to withdraw from the study at any time.

Statistical Analysis

Continuous and categorical data are presented as medians (interquartile range) and number (%) of individuals, respectively. The patients were categorized into four groups based on the combination of the presence or absence of PS and dysphagia: non-PS and non-dysphagia, non-PS and dysphagia, PS and non-dysphagia, and PS and dysphagia groups. Analysis of variance and chi-square tests were used for comparisons between the groups. To assess the potential for attrition bias in this study, clinical characteristics were compared between patients included in the final analysis and those lost to follow-up using the Mann–Whitney U test and the chi-square test. A modified Poisson regression analysis was conducted with the combinations of PS and dysphagia as independent variables and poor functional outcome as the dependent variable to examine the association between each combination and the outcome. The covariates included age, sex, BMI, NIHSS score, stroke type, hypertension, previous stroke, diabetes mellitus, dyslipidemia, atrial fibrillation, heart failure, and premorbid disability (premorbid mRS score of >2). These variables were selected based on previous studies reporting stroke outcomes, considering their clinical relevance.28,30-32) The p-value for trend was obtained by incorporating an ordinal variable (coded 1–4 according to PS and dysphagia status) into the fully adjusted modified Poisson regression model including all covariates. Furthermore, a modified Poisson regression analysis, including dysphagia, PS, and their interaction terms (PS×dysphagia), was performed simultaneously to evaluate the interaction between sarcopenia and dysphagia. This analysis specifically aimed to determine whether the combined effect of PS and dysphagia on poor functional outcomes was additive, or if there was an additional synergistic effect beyond the sum of their individual impacts. As sensitivity analyses, the same analyses were performed in the following subgroups: (1) after excluding patients with bilateral paralysis, and (2) using an alternative definition of dysphagia as a FOIS score of 6 or less, which included patients with mild dysphagia. Statistical analyses were performed using Statistical Package for the Social Sciences version 28.0 (IBM Corp., Tokyo, Japan). A p-value of less than 0.05 was considered statistically significant.

RESULTS

The study flowchart is shown in Fig. 1. During the study period, 1,124 patients with stroke were admitted to the hospital. Of these, 253 were excluded: 222 with missing data, 29 with a premorbid mRS score of 5, and two with COVID-19. Additionally, 250 patients did not return the questionnaire after 12 months or could not be followed up by using their medical records, and 17 who declined to participate. The final analysis included 604 patients. Table 1 shows the characteristics of the patients in each group. The median age (interquartile range) of the cohort was 76 (67–84) years, and 367 (60.8%) patients were men. The number of patients in each group was as follows: non-PS and non-dysphagia group, 281 (46.5%); non-PS and dysphagia group, 61 (10.1%); PS and non-dysphagia group, 187 (31.0%); and PS and dysphagia group, 75 (12.4%). Supplementary Table S1 shows a comparison of baseline characteristics between the 604 patients included in the final analysis and the 250 patients excluded due to loss to follow-up. Compared with patients included in the analysis, those excluded were significantly older, had higher NIHSS score, higher mRS score both premorbid and at discharge, and had lower handgrip strength and smaller calf circumference.
Fig. 2 shows the number and proportion of patients with poor functional outcomes in each group. Poor functional outcomes were observed in 22 (7.8%), 16 (26.2%), 74 (39.6%), and 63 (84.0%) patients in the non-PS and non-dysphagia, non-PS and dysphagia, PS and non-dysphagia, and PS and dysphagia groups, respectively. Fig. 3 shows the results of the modified Poisson regression analysis for poor functional outcomes. When the non-PS and non-dysphagia group was used as the reference, the risk ratios (RRs) and 95% confidence interval (CI) for each group were as follows: non-PS and dysphagia group, 2.096 (95% CI 1.160–3.789); PS and non-dysphagia group, 2.830 (95% CI 1.725–4.643); and PS and dysphagia group, 3.868 (95% CI 2.224–6.725). In this analysis, the dispersion parameter (φ) was 0.811. The Akaike Information Criterion (AIC) was 658.544 for the fully adjusted model and 672.078 for the crude model. When the groups were treated as ordinal variables, the p-value for trend was found to be significant (p<0.001). Fig. 4 shows the results of the modified Poisson regression analysis including dysphagia, PS, and the interaction term (PS×dysphagia) simultaneously. The RR for each variable was as follows: dysphagia, 1.449 (95% CI 1.133–1.854); PS, 2.322 (95% CI 1.531–3.523); and PS×dysphagia, 4.348 (95% CI 2.683–7.046). In this analysis, the φ was 0.815. The AIC was 661.548 for the fully adjusted model and 686.358 for the crude model. Sensitivity analysis results are presented in the Supplementary Figs. S1S4. Across analyses excluding patients with bilateral paralysis and redefining dysphagia as the FOIS score of 6 or less, the PS and dysphagia group consistently showed significantly higher RRs compared with the non-PS and non-dysphagia group, and the PS×dysphagia interaction terms were statistically significant. All subgroup analyses demonstrated trends consistent with the main results.
Table 2 shows adverse events up to 12 months after onset for each group. There were no significant differences in the incidence of MACEs among the groups (recurrent stroke, p=0.166; other cardiovascular diseases, p=0.197). For non-MACEs, significant intergroup differences were observed for pneumonia and other medical conditions (both p<0.001). Specifically, the incidence of pneumonia was as follows: non-PS and non-dysphagia group, three patients (1.1%); non-PS and dysphagia group, six patients (9.8%); PS and non-dysphagia group, seven patients (3.7%); and PS and dysphagia group, nine patients (12.0%). The incidences of other medical conditions were as follows: non-PS and non-dysphagia group, five patients (1.8%); non-PS and dysphagia group, six patients (9.8%); PS and non-dysphagia group, 18 patients (9.6%); and PS and dysphagia group, nine patients (12.0%). All-cause mortality was also significantly different among the groups (p<0.001): non-PS and non-dysphagia group, two patients (0.7%); non-PS and dysphagia group, five patients (8.2%); PS and non-dysphagia group, 19 patients (10.2%); and PS and dysphagia group, 15 patients (20.0%).

DISCUSSION

This study investigated the relationship between the co-existence of PS and dysphagia and functional prognosis in patients with acute stroke. The results revealed a significant association between the co-existence of PS and dysphagia and poor functional outcomes at 12 months after stroke, with a significant interaction observed. This suggests that the two risk factors do not merely exert additive effects but mutually augment their adverse impacts.
The co-existence of PS and dysphagia is associated with poor functional outcomes and exhibits an interaction effect. While previous studies have reported sarcopenia alone11,33,34) and dysphagia alone35-37) as independent risk factors for poor outcomes after stroke, this study is unique in demonstrating for the first time that these two conditions do not merely exacerbate functional prognosis independently, but amplify their effects, leading to a more severe disability trajectory. Several mechanisms can explain this interaction. One pathway involves the difficulty in achieving adequate nutritional intake due to dysphagia, which accelerates the progression of sarcopenia. Malnutrition suppresses muscle protein synthesis and promotes muscle breakdown, thereby worsening sarcopenia.38-40) Severe dysphagia often necessitates the use of a tube feeding, which, combined with reduced physical activity, can lead to further loss of muscle mass and strength. Conversely, systemic sarcopenia implies generalized muscle weakness, including in the swallowing muscles, which can delay the recovery of the swallowing function and lead to more severe dysphagia.41,42) It should also be noted that, given the study design, sarcopenia may reflect a pre-existing condition prior to stroke onset. Therefore, when interpreting the interactions in this study, it may be natural to consider a temporal framework: the recovery trajectory is modified when dysphagia—a direct functional consequence of stroke—is superimposed on a pre-existing state of reduced physical reserve, such as sarcopenia. It is plausible that these vicious cycles interact, diminishing the effectiveness of rehabilitation, and consequently leading to a substantial deterioration in long-term functional prognosis.
This study found a potential association between the co-existence of PS and dysphagia and the incidence of medical conditions including pneumonia. This may be another potential factor contributing to poor functional outcomes. Dysphagia is the primary factor that increases the risk of aspiration pneumonia.43) Sarcopenia is associated with impaired immunity and reduced pulmonary function.44-46) Therefore, when both conditions coexist, a systemic state prone to severe complications may be formed, which can lead to increased medical interventions, interruptions in rehabilitation, and further physical decline, thus potentially contributing to poor functional outcomes at 12 months after stroke.
The results of this study indicate the importance of early screening for PS and dysphagia in patients with acute stroke in order to identify high-risk patients with coexisting conditions. Implementing multifaceted interventions that combine early and intensive swallowing rehabilitation, nutritional management, and exercise therapy could potentially break the vicious cycle of sarcopenia and dysphagia, prevent complications such as pneumonia, and ultimately improve functional outcomes. Given the demonstrated interaction, it is crucial not only to treat each condition individually but also to implement a dual therapeutic cycle of rehabilitation and nutritional treatment that considers their mutual relationship.47) For example, chair-stand exercises have been shown to improve not only sarcopenia but also swallowing function in patients with stroke.48,49) Furthermore, frequent and individualized nutritional support can lead to improvements in nutritional status, activities of daily living, and swallowing function after stroke.50) Future prospective studies should investigate the potential of multifaceted interventions targeting both sarcopenia and dysphagia. Such studies should also evaluate the dose of rehabilitation after admission and explore potential mitigating factors, such as the interaction between rehabilitation intensity and the risk of complications (e.g., reduced pneumonia risk with a higher rehabilitation dose in patients with dysphagia), to further optimize patient outcomes.
This study had several limitations. First, it was conducted at only two acute care hospitals in Japan, which may limit the generalizability of the results. Second, a considerable number of participants were excluded because of missing data, potentially leading to selection bias. Comparison of baseline characteristics between patients excluded during follow-up and those included in the analysis showed that excluded patients were older, had more severe stroke, and poorer physical function. Therefore, the possibility of attrition bias among patients with these characteristics cannot be ruled out. Third, owing to the retrospective design of the study, it was difficult to establish causality. Fourth, we could not fully adjust for the influence of confounding factors such as genetic, social, and clinical variables, which could contribute to poor functional outcomes. In particular, premorbid mRS differed across the groups. Although this factor was adjusted for in the statistical models, potential residual differences in baseline patient characteristics cannot be ruled out. Thus, pre-existing functional limitations and related vulnerability may have contributed to the observed outcomes. Fifth, the robustness of the definitions of sarcopenia and dysphagia may have been limited. According to the AWGS criteria, a definitive diagnosis of sarcopenia requires body composition analysis, in addition to grip strength and calf circumference.24) Furthermore, detailed dysphagia assessments, such as videoendoscopic or videofluoroscopic swallowing studies, were not performed; therefore, the accuracy of the FOIS classification in fully capturing dysphagia severity may be limited. In addition, owing to the retrospective design, the reasons underlying clinicians’ decisions to initiate tube feeding could not be fully ascertained, and the possibility of selection bias cannot be excluded. Future studies incorporating objective assessments such as videoendoscopic and/or videofluoroscopic swallowing studies are warranted.
In conclusion, this study demonstrated that the co-existence of PS and dysphagia in patients with acute stroke is associated with poor functional outcomes at 12 months after stroke onset and that a significant interaction exists between the two. These findings suggest that early screening for sarcopenia and dysphagia, along with integrated intervention strategies that consider their interaction, is indispensable for improving the long-term prognosis after stroke. Future studies should include prospective interventional studies to validate the effectiveness of multifaceted intervention programs for high-risk patients.

ACKNOWLEDGMENTS

We express our deepest gratitude to the Rehabilitation Center of Uonuma Kikan Hospital and the Konan Medical Center for their support.

CONFLICT OF INTEREST

The researchers claim no conflicts of interest.

FUNDING

None.

AUTHOR CONTRIBUTIONS

Conceptualization, YS, TA, KO, AS, KY; Data curation, YS, TA, KO, AS, KY; Formal analysis, YS; Writing_original draft, YS; Writing_review & editing, YS, YK, ST, KI, MN.

SUPPLEMENTARY MATERIALS

Supplementary materials can be found via https://doi.org/10.4235/agmr.26.0002.
Table S1.
Comparison of baseline characteristics of patients included in the study and those excluded at follow-up
agmr-26-0002-Supplementary-Table-S1.pdf
Fig. S1.
The modified Poisson regression analysis for poor functional outcomes in the subgroup excluding patients with bilateral paralysis. Dots represent risk ratios for fully adjusted model including all covariates, and error bars indicate 95% confidence intervals. PS, possible sarcopenia.
agmr-26-0002-Supplementary-Fig-S1.pdf
Fig. S2.
The modified Poisson regression analysis of the interaction term between possible sarcopenia and dysphagia for poor functional outcomes in the subgroup excluding patients with bilateral paralysis. Dots represent risk ratios for fully adjusted model including all covariates, and error bars indicate 95% confidence intervals. PS, possible sarcopenia.
agmr-26-0002-Supplementary-Fig-S2.pdf
Fig. S3.
The modified Poisson regression analysis for poor functional outcomes in patients with dysphagia defined as the Functional Oral Intake Scale score 6 or less. Dots represent risk ratios for fully adjusted model including all covariates, and error bars indicate 95% confidence intervals. PS, possible sarcopenia.
agmr-26-0002-Supplementary-Fig-S3.pdf
Fig. S4.
The modified Poisson regression analysis of the interaction term between possible sarcopenia and dysphagia for poor functional outcomes in patients with dysphagia defined as the Functional Oral Intake Scale score 6 or less. Dots represent risk ratios for fully adjusted model including all covariates, and error bars indicate 95% confidence intervals. PS, possible sarcopenia.
agmr-26-0002-Supplementary-Fig-S4.pdf

Fig. 1.
Flowchart of the study. mRS, modified Rankin Scale.
agmr-26-0002f1.jpg
Fig. 2.
The number and proportion of patients with poor functional outcomes in each group. Numbers within the bar graph indicate the number of patients. Each group was normalized to 100%. PS, possible sarcopenia.
agmr-26-0002f2.jpg
Fig. 3.
The modified Poisson regression analysis for poor functional outcomes. Dots represent risk ratios for fully adjusted model including all covariates, and error bars indicate 95% confidence intervals. PS, possible sarcopenia.
agmr-26-0002f3.jpg
Fig. 4.
The modified Poisson regression analysis of the interaction term between possible sarcopenia and dysphagia for poor functional outcomes. Dots represent risk ratios for fully adjusted model including all covariates, and error bars indicate 95% confidence intervals. PS, possible sarcopenia.
agmr-26-0002f4.jpg
Table 1.
Patient characteristics
Non-PS and non-dysphagia (n=281) Non-PS and dysphagia (n=61) PS and non-dysphagia (n=187) PS and dysphagia (n=75) p-value
Age (y) 70 (61–77) 81 (69–86) 83 (75–86) 90 (78–93) <0.001
Sex, male 206 (73.3) 36 (59.0) 95 (50.8) 30 (40.0) <0.001
BMI (kg/m2) 24.0 (22.0–26.1) 23.6 (22.0–25.7) 21.3 (19.4–23.6) 20.3 (18.4–23.1) <0.001
NIHSS score 2 (1–4) 5 (3–8) 4 (2–7) 8 (5–13) <0.001
Stroke type 0.057
 Infarct 222 41 150 52
 Hemorrhage 59 20 37 23
Side of lesion 0.050
 Right 155 31 84 28
 Left 118 26 91 41
 Both 8 4 12 6
Comorbidity
 Hypertension 190 (67.6) 45 (73.8) 128 (68.4) 46 (61.3) 0.481
 Diabetes mellitus 80 (28.5) 14 (23.0) 52 (27.8) 16 (21.3) 0.552
 Previous stroke 50 (17.8) 11 (18.0) 49 (26.2) 15 (20.0) 0.159
 Dyslipidemia 76 (27.0) 16 (26.2) 53 (28.3) 15 (20.0) 0.573
 Atrial fibrillation 31 (11.0) 15 (24.6) 26 (13.9) 20 (26.7) 0.001
 Heart failure 6 (2.1) 4 (6.6) 14 (7.5) 11 (14.7) <0.001
Recanalization therapy 0.527
 Thrombolysis 12 (4.3) 0 (0.0) 0 (0.0) 2 (2.7)
 Thrombectomy 5 (1.8) 3 (4.9) 7 (3.7) 4 (5.3)
Length of hospital stay (day) 15 (10–21) 25 (16–35) 18 (12–26) 24 (19–31) <0.001
Premorbid mRS <0.001
 0 238 (84.7) 44 (72.1) 107 (57.2) 28 (37.3)
 1 24 (8.5) 7 (11.5) 16 (8.6) 16 (21.3)
 2 8 (2.8) 2 (3.3) 20 (10.7) 6 (8.0)
 3 6 (2.1) 7 (11.5) 32 (17.1) 18 (24.0)
 4 5 (1.8) 1 (1.6) 12 (6.4) 7 (9.3)
mRS at discharge <0.001
 0 72 (25.6) 5 (8.2) 12 (6.4) 0 (0.0)
 1 88 (31.3) 10 (16.4) 22 (11.8) 1 (1.3)
 2 46 (16.4) 13 (21.3) 30 (16.0) 7 (9.3)
 3 44 (15.7) 13 (21.3) 45 (24.1) 14 (18.7)
 4 29 (10.3) 14 (23.0) 69 (36.9) 36 (48.0)
 5 2 (0.7) 2 (3.3) 8 (4.3) 17 (22.7)
 6 0 (0.0) 4 (6.6) 1 (0.5) 0 (0.0)
Grip strength at admission (kg)
 Males 33.0 (28.6–38.4) 29.1 (28.1–30.2) 20.0 (13.5–23.7) 14.3 (5.8-18.5) <0.001
 Females 19.0 (15.9–21.2) 18.3 (14.5–20.4) 12.1 (9.4–15.1) 8.9 (5.3-13.4) <0.001
CC at admission (cm)
 Males 36.0 (34.0–37.4) 35.5 (34.5–37.1) 31.5 (29.5–32.5) 30.5 (28.6-32.3) <0.001
 Females 33.5 (31.3–35.0) 33.5 (31.0–35.0) 29.8 (27.5–31.0) 28.5 (26.5-31.5) <0.001
FOIS at admission (point) 6 (5–7) 1 (1–3) 5 (5–7) 1 (1–3) <0.001

Values are presented as median (interquartile range) or number (%).

PS, possible sarcopenia; BMI, body mass index; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; CC, calf circumference; FOIS, Functional Oral Intake Scale.

Table 2.
Adverse events up to 12 months post-onset for each group
Non-PS and non-dysphagia (n=281) Non-PS and dysphagia (n=61) PS and non-dysphagia (n=187) PS and dysphagia (n=75) p-value
MACE
 Recurrent stroke 13 (4.6) 5 (8.2) 18 (9.6) 7 (9.3) 0.166
 Other cardiovascular disease 3 (1.1) 1 (1.6) 7 (3.7) 3 (4.0) 0.197
Non-MACE
 Pneumonia 3 (1.1) 6 (9.8) 7 (3.7) 9 (12.0) <0.001
 Other internal disease 5 (1.8) 6 (9.8) 18 (9.6) 9 (12.0) <0.001
 Fall 2 (0.7) 1 (1.6) 5 (2.7) 2 (2.7) 0.362
 Other 10 (3.6) 4 (6.6) 16 (8.6) 6 (8.0) 0.125
All-cause mortality 2 (0.7) 5 (8.2) 19 (10.2) 15 (20.0) <0.001

Values are presented as median (interquartile range) or number (%).

PS, possible sarcopenia; MACE, major adverse cardiovascular events.

REFERENCES

1. Seminog OO, Scarborough P, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute stroke in England: linked national database study of 795 869 adults. BMJ 2019;365:l1778.
crossref pmid pmc
2. Tziaka E, Tsiakiri A, Vlotinou P, Christidi F, Tsiptsios D, Aggelousis N, et al. A holistic approach to expressing the burden of caregivers for stroke survivors: a systematic review. Healthcare (Basel) 2024;12:565.
crossref pmid pmc
3. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021;20:795-820.
crossref pmid pmc
4. Silva CR, Pimenta CJ, Viana LR, Ferreira GR, Bezerra TA, Costa TF, et al. Specific health-related quality of life in cerebrovascular accident survivors: associated factors. Rev Bras Enferm 2021;75:e20210407.
crossref pmid
5. Chang WH, Sohn MK, Lee J, Kim DY, Lee SG, Shin YI, et al. Predictors of functional level and quality of life at 6 months after a first-ever stroke: the KOSCO study. J Neurol 2016;263:1166-77.
crossref pmid pdf
6. Obaid M, Flach C, Marshall I, D A Wolfe C, Douiri A. Long-term outcomes in stroke patients with cognitive impairment: a population-based study. Geriatrics (Basel) 2020;5:32.
crossref pmid pmc
7. Kim SY, Cho WS, Park CB, Kim BG. Effect of sarcopenia on functional recovery in acute stroke patients admitted for standard rehabilitation program. Medicina (Kaunas) 2024;60:1716.
crossref pmid pmc
8. Yoshimura Y, Wakabayashi H, Bise T, Nagano F, Shimazu S, Shiraishi A, et al. Sarcopenia is associated with worse recovery of physical function and dysphagia and a lower rate of home discharge in Japanese hospitalized adults undergoing convalescent rehabilitation. Nutrition 2019;61:111-8.
crossref pmid
9. Su Y, Yuki M, Otsuki M. Prevalence of stroke-related sarcopenia: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2020;29:105092.
crossref pmid
10. Inoue T, Ueshima J, Kawase F, Kobayashi H, Nagano A, Murotani K, et al. Trajectories of the prevalence of sarcopenia in the pre- and post-stroke periods: a systematic review. Nutrients 2022;15:113.
crossref pmid pmc
11. Chen R, Liu Z, Liao R, Liang H, Hu C, Zhang X, et al. The effect of sarcopenia on prognosis in patients with mild acute ischemic stroke: a prospective cohort study. BMC Neurol 2025;25:130.
crossref pmid pmc pdf
12. Feng MC, Lin YC, Chang YH, Chen CH, Chiang HC, Huang LC, et al. The mortality and the risk of aspiration pneumonia related with dysphagia in stroke patients. J Stroke Cerebrovasc Dis 2019;28:1381-7.
crossref pmid
13. Labeit B, Michou E, Hamdy S, Trapl-Grundschober M, Suntrup-Krueger S, Muhle P, et al. The assessment of dysphagia after stroke: state of the art and future directions. Lancet Neurol 2023;22:858-70.
crossref pmid
14. Zhao WT, Yang M, Wu HM, Yang L, Zhang XM, Huang Y. Systematic review and meta-analysis of the association between sarcopenia and dysphagia. J Nutr Health Aging 2018;22:1003-9.
crossref pmid pmc pdf
15. Fujishima I, Fujiu-Kurachi M, Arai H, Hyodo M, Kagaya H, Maeda K, et al. Sarcopenia and dysphagia: position paper by four professional organizations. Geriatr Gerontol Int 2019;19:91-7.
crossref pmid pdf
16. Maeda K, Akagi J. Sarcopenia is an independent risk factor of dysphagia in hospitalized older people. Geriatr Gerontol Int 2016;16:515-21.
crossref pmid
17. Cha S, Kim WS, Kim KW, Han JW, Jang HC, Lim S, et al. Sarcopenia is an independent risk factor for dysphagia in community-dwelling older adults. Dysphagia 2019;34:692-7.
crossref pmid pdf
18. Fukuma K, Kamada M, Yamamoto K, Yokota C, Abe S, Nakazawa S, et al. Pre-existing sarcopenia and swallowing outcomes in acute stroke patients. Clin Nutr 2023;42:1454-61.
crossref pmid
19. Campo-Rivera N, Ocampo-Chaparro JM, Carvajal-Ortiz R, Reyes-Ortiz CA. Sarcopenic dysphagia is associated with mortality in institutionalized older adults. J Am Med Dir Assoc 2022;23:1720.
crossref
20. Attrill S, White S, Murray J, Hammond S, Doeltgen S. Impact of oropharyngeal dysphagia on healthcare cost and length of stay in hospital: a systematic review. BMC Health Serv Res 2018;18:594.
crossref pmid pmc pdf
21. Patel DA, Krishnaswami S, Steger E, Conover E, Vaezi MF, Ciucci MR, et al. Economic and survival burden of dysphagia among inpatients in the United States. Dis Esophagus 2018;31:1-7.
crossref
22. Sato Y, Yoshimura Y, Abe T. Nutrition in the first week after stroke is associated with discharge to home. Nutrients 2021;13:943.
crossref pmid pmc
23. Miyamoto S, Ogasawara K, Kuroda S, Itabashi R, Toyoda K, Itoh Y, et al. Japan Stroke Society guideline 2021 for the treatment of stroke. Int J Stroke 2022;17:1039-49.
crossref pmid pmc pdf
24. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300-7.
crossref pmid
25. Crary MA, Mann GD, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil 2005;86:1516-20.
crossref pmid
26. Ikenouchi H, Nozue K, Yamaguchi S, Miyamoto T, Ikeda K, Yamamoto N, et al. Enteral tube nutrition for geriatric post-stroke dysphagia evaluation (ENGE) score to evaluate the risk of dysphagia after acute ischemic stroke. J Neurol Sci 2023;455:122801.
crossref pmid
27. Kushner DS, Johnson-Greene D, Cordero MK, Thomashaw SA, Rodriguez J. Swallowing outcomes and discharge destinations in acute stroke tube-feeding dependent dysphagia patients treated with neuromuscular electrical stimulation during inpatient rehabilitation. Am J Phys Med Rehabil 2020;99:487-94.
crossref pmid
28. Sato Y, Abe T, Kimura Y, Tanaka S, Okuda K, Shirahata A, et al. Initial calf circumference predicts poor disability outcomes in patients with stroke. J Nutr Health Aging 2025;29:100483.
crossref pmid pmc
29. Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002;33:2243-6.
crossref pmid
30. Abe T, Sato Y, Kimura Y, Tanaka S, Okuda K, Shirahata A, et al. Impact of possible sarcopenia on post-discharge adverse outcomes in patients with acute stroke. Clin Nutr ESPEN 2025;69:13-9.
crossref pmid
31. Craig LE, Wu O, Bernhardt J, Langhorne P. Predictors of poststroke mobility: systematic review. Int J Stroke 2011;6:321-7.
crossref pmid pdf
32. Preston E, Ada L, Dean CM, Stanton R, Waddington G. What is the probability of patients who are nonambulatory after stroke regaining independent walking?: a systematic review. Int J Stroke 2011;6:531-40.
crossref pmid pdf
33. Kim KY, Jung S, Cho EB, Yang TW, Kim SJ, Kim H, et al. The impact of reduced skeletal muscle mass at stroke onset on 3-month functional outcomes in acute ischemic stroke patients. PLoS One 2025;20:e0313368.
crossref pmid pmc
34. Ogino T, Nozoe M, Inoue T, Ishida M, Yamamoto K. Impact of possible sarcopenia on functional prognosis in patients with acute stroke with premorbid disability. Geriatr Gerontol Int 2024;24:359-63.
crossref pmid pmc
35. Karisik A, Moelgg K, Buergi L, Scherer L, Dejakum B, Felicetti S, et al. Impact of dysphagia on early psychosocial consequences after acute ischemic stroke. J Neurol Sci 2025;476:123624.
crossref pmid
36. Hamada T, Yoshimura Y, Nagano F, Matsumoto A, Shimazu S, Shiraishi A, et al. Prognostic value of dysphagia for activities of daily living performance and cognitive level after stroke. Prog Rehabil Med 2024;9:20240005.
crossref pmid pmc
37. Falsetti P, Acciai C, Palilla R, Bosi M, Carpinteri F, Zingarelli A, et al. Oropharyngeal dysphagia after stroke: incidence, diagnosis, and clinical predictors in patients admitted to a neurorehabilitation unit. J Stroke Cerebrovasc Dis 2009;18:329-35.
crossref pmid
38. Cruz-Jentoft AJ, Kiesswetter E, Drey M, Sieber CC. Nutrition, frailty, and sarcopenia. Aging Clin Exp Res 2017;29:43-8.
crossref pmid pdf
39. Barone M, Baccaro P, Molfino A. An overview of sarcopenia: focusing on nutritional treatment approaches. Nutrients 2025;17:1237.
crossref pmid pmc
40. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010;91:1123S-1127S.
crossref pmid
41. Maeda K, Ishida Y, Nonogaki T, Shimizu A, Yamanaka Y, Matsuyama R, et al. Development and predictors of sarcopenic dysphagia during hospitalization of older adults. Nutrients 2019;12:70.
crossref pmid pmc
42. Nishioka S, Fujishima I, Kishima M, Ohno T, Shimizu A, Shigematsu T, et al. Association of existence of sarcopenia and poor recovery of swallowing function in post-stroke patients with severe deglutition disorder: a multicenter cohort study. Nutrients 2022;14:4115.
crossref pmid pmc
43. Labeit B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, Muhle P, Bath PM, et al. Dysphagia after stroke: research advances in treatment interventions. Lancet Neurol 2024;23:418-28.
crossref pmid
44. Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: the potential role of an aged immune system. Ageing Res Rev 2017;36:1-10.
crossref pmid
45. Zhang X, Li H, He M, Wang J, Wu Y, Li Y. Immune system and sarcopenia: presented relationship and future perspective. Exp Gerontol 2022;164:111823.
crossref pmid
46. Kong S, Shin S, Lee JK, Lee G, Kang D, Cho J, et al. Association between sarcopenia and physical function among preoperative lung cancer patients. J Pers Med 2020;10:166.
crossref pmid pmc
47. Kakehi S, Isono E, Wakabayashi H, Shioya M, Ninomiya J, Aoyama Y, et al. Sarcopenic dysphagia and simplified rehabilitation nutrition care process: an update. Ann Rehabil Med 2023;47:337-47.
crossref pmid pmc pdf
48. Yoshimura Y, Wakabayashi H, Nagano F, Bise T, Shimazu S, Shiraishi A, et al. Chair-stand exercise improves sarcopenia in rehabilitation patients after stroke. Nutrients 2022;14:461.
crossref pmid pmc
49. Yoshimura Y, Wakabayashi H, Nagano F, Bise T, Shimazu S, Shiraishi A. Chair-stand exercise improves post-stroke dysphagia. Geriatr Gerontol Int 2020;20:885-91.
crossref pmid
50. Shimazu S, Yoshimura Y, Kudo M, Nagano F, Bise T, Shiraishi A, et al. Frequent and personalized nutritional support leads to improved nutritional status, activities of daily living, and dysphagia after stroke. Nutrition 2021;83:111091.
crossref pmid


ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#401 Yuksam Hyundai Venturetel, 20, Teheran-ro 25-gil, Gangnam-gu, Seoul 06132, Korea
Tel: +82-2-2269-1039    Fax: +82-2-2269-1040    E-mail: agmr.editorial@gmail.com                

Copyright © 2026 by Korean Geriatrics Society.

Developed in M2PI

Close layer
prev next